Baseline characteristics of anaplastict thyroid cancer (ATC) patients treated with pembrolizumab added as a salvage therapy to kinase inhibitor therapy
| N = 12 | |
|---|---|
| Median Age at treatment start, years (range) | 60 (47–84) |
| Gender, n (%) | |
| Men Women | 8 (67)4 (33) |
| Ethnicity, n (%) | |
| Caucasian Asian Black | 9 (75)2 (16)1 (9) |
| Stage at Diagnosis, n (%) | |
| IVA IVB IVC | 0 (0)3 (25)9 (75) |
| Pathology, n (%) | |
| ATC only Papillary thyroid cancer + ATC Poorly differentiated thyroid cancer + ATC Follicular thyroid cancer +ATC | 4 (33)4 (33)3 (25)1 (9) |
| PD-L1 status, n (%) < 10% 11–50% 51–100% | 10 (83)2 (20)4 (40)4 (40) |
| Performance Status, n (%) | |
| ECOG 0 ECOG 1 ECOG 2 | 2 (16)6 (50)4 (33) |
| Previous Treatment for ATC, n (%)a | |
| Surgery, n (%) Radiation/chemosensitizing, n (%) Bridging Chemotherapy, n (%)b | 5 (41)6 (50)3 (25) |
| Targeted therapyc, n (%) | |
| Lenvatinib Dabrafenib + trametinib Trametinib alone | 5 (41)6 (50)1 (9) |
aPatients received more than 1 modality of therapy
bChemotherapy as a bridging therapy while awaiting targeted therapy
cAll patients with BRAFV600E mutations were treated with dabrafenib + trametinib